Clinical Trial

Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a Phase 1, multi-center, open-label study with a dose-escalation phase (Phase 1a) and a cohort expansion phase (Phase 1b), to evaluate the safety, tolerability, and PK profile of LP-118 under a once daily oral dosing schedule in up to 100 subjects.
Protocol Amendment History 13 amendments
This ClinicalTrials.gov record has been amended 13 times since 2021-02-23; most recent amendment 2026-04-29.
Status change: Not Yet Recruiting → Recruiting 2021-08-24
Trial Details
NCT Number NCT04771572
Lead Sponsor Newave Pharmaceutical Inc
Conditions Non Hodgkin Lymphoma, Richter Transformation, Multiple Myeloma, T-cell-prolymphocytic Leukemia, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Myeodysplastic Syndrome, Myelodysplastic/Myeloproliferative Neoplasm +5 more
Enrollment 100 participants
Start Date 2022-05-08
Primary Completion 2026-12-31 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-05-05